Encyt is at the forefront of groundbreaking cancer research, pioneering novel therapeutic approaches to disrupt treatment-induced cancer stem cell proliferation. Our studies have identified a highly conserved inflammatory response triggered after surgery, chemotherapy, or radiation, which accelerates cancer regrowth and resistance.

In collaboration with the Dr. Szewczuk Laboratory at Queen’s University, our research has demonstrated a 90% reduction in pancreatic tumor growth in preclinical models, alongside significant improvements in ovarian and breast cancer treatments. As we prepare for our first human clinical trial in 2025 for patients with metastatic pancreatic cancer, Encyt remains dedicated to optimizing cancer therapies by targeting critical cytokine responses within a key treatment window.

With patents pending and early-stage clinical trials underway, we are seeking additional funding to expand our research and bring innovative cancer treatments to patients worldwide.